This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
AHCPR-Funded Study Finds Progression of HIV
Disease Not Related to Race, Sex, or Drug Use
Press Release Date: September 20, 1995
A new study being published in the September 21, 1995, issue of
The New England Journal of
Medicine examines the relationships of race, sex, and drug
use to progression of HIV disease.
The rates of progression of HIV infection and survival have been
reported in a number of earlier
studies to differ between sociodemographic groups, though it has
remained unclear whether these
differences reflected biologic differences or differences in
access to medical care.
The researchers concluded that among patients with HIV infection
who received medical care
from a single urban center, there were no differences in disease
progression or survival associated
with sex, race, injection-drug use, or socioeconomic status.
Differences found in other studies
may reflect differences in the use of medical care.
Researchers at The Johns Hopkins University School of Medicine in
Baltimore, supported by an
AHCPR research grant, measured disease progression and survival
in a cohort of 1,372 patients
who were seropositive for HIV, and who were treated at a single
urban center. Median follow-up
was 1.6 years. They calculated the rates of survival for the
entire cohort and the rates of
progression to the acquired immunodeficiency syndrome (AIDS) or
death in 740 patients who
presented without AIDS.
In the entire cohort, a lower CD4 cell count, a diagnosis of
AIDS, older age, and the receipt of
antiretroviral therapy before enrollment were associated with an
increased risk of death. The use
of prophylaxis against pneumocystis pneumonia, zidovudine use
after enrollment, and having a job
at base line were associated with lower risks of death. The
researchers found no significant
difference in survival between men and women, blacks and whites,
injection-drug users and those
who did not use drugs, or patients whose median annual incomes
were $5,000 or less and those
whose incomes were more than $5,000. They found no relation
between disease progression and
sex, race, injection-drug use, income, level of education, or
Note: The article in the September 21, 1995 issue of The New
England Journal of Medicine is
entitled "Race, Sex, Drug Use, and Progression of Human
Immunodeficiency Virus Disease," by
Richard E. Chaisson, MD, Jeanne C. Keruly, BSN, and Richard D.
Moore, M.D., M.H.Sc.
For assistance in arranging interviews, or for information on
other AHCPR-funded research
projects on cost, quality and access to health care, contact
AHCPR Public Affairs: Karen Migdail, (301) 427-1855.